Group One Trading
NTLA icon

Group One Trading’s Intellia Therapeutics NTLA Stock Holding History

Group One Trading’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
83,600
+8,900
+12% +$113K ﹤0.01% 2643
2025
Q4 		$672K Sell
74,700
-42,600
-36% -$586K ﹤0.01% 3234
2025
Q3 		$2.03M Buy
117,300
+35,500
+43% +$437K ﹤0.01% 2310
2025
Q2 		$767K Buy
81,800
+14,500
+22% +$119K ﹤0.01% 3010
2025
Q1 		$479K Buy
67,300
+3,500
+5% +$35.4K ﹤0.01% 3131
2024
Q4 		$744K Buy
63,800
+17,700
+38% +$276K ﹤0.01% 2839
2024
Q3 		$947K Buy
46,100
+23,300
+102% +$537K ﹤0.01% 2337
2024
Q2 		$510K Sell
22,800
-12,300
-35% -$293K ﹤0.01% 2547
2024
Q1 		$966K Sell
35,100
-39,300
-53% -$1.09M ﹤0.01% 2121
2023
Q4 		$2.27M Buy
74,400
+59,700
+406% +$1.72M 0.01% 1763
2023
Q3 		$465K Sell
14,700
-14,500
-50% -$563K ﹤0.01% 2988
2023
Q2 		$1.19M Buy
29,200
+16,800
+135% +$681K ﹤0.01% 2193
2023
Q1 		$462K Sell
12,400
-14,200
-53% -$557K ﹤0.01% 2849
2022
Q4 		$928K Buy
26,600
+1,900
+8% +$90.3K ﹤0.01% 2482
2022
Q3 		$1.38M Sell
24,700
-17,200
-41% -$1.07M ﹤0.01% 2241
2022
Q2 		$2.17M Buy
41,900
+5,800
+16% +$295K ﹤0.01% 1986
2022
Q1 		$2.62M Sell
36,100
-2,400
-6% -$203K ﹤0.01% 2122
2021
Q4 		$4.55M Sell
38,500
-28,000
-42% -$3.51M ﹤0.01% 1788
2021
Q3 		$8.92M Sell
66,500
-92,000
-58% -$13.9M 0.01% 1161
2021
Q2 		$25.7M Buy
158,500
+124,800
+370% +$9.72M 0.03% 495
2021
Q1 		$2.71M Buy
33,700
+20,900
+163% +$1.4M ﹤0.01% 2134
2020
Q4 		$696K Buy
12,800
+11,300
+753% +$410K ﹤0.01% 2971
2020
Q3 		$30K Sell
1,500
-7,800
-84% -$163K ﹤0.01% 4938
2020
Q2 		$195K Buy
9,300
+4,700
+102% +$79.8K ﹤0.01% 3397
2020
Q1 		$56K Sell
4,600
-17,800
-79% -$240K ﹤0.01% 3642
2019
Q4 		$329K Buy
22,400
+11,000
+96% +$153K ﹤0.01% 2787
2019
Q3 		$152K Buy
11,400
+6,300
+124% +$100K ﹤0.01% 3274
2019
Q2 		$83K Sell
5,100
-1,500
-23% -$23.6K ﹤0.01% 3489
2019
Q1 		$113K Buy
6,600
+200
+3% +$2.98K ﹤0.01% 3091
2018
Q4 		$87K Sell
6,400
-16,900
-73% -$314K ﹤0.01% 3260
2018
Q3 		$667K Sell
23,300
-12,600
-35% -$367K 0.01% 2026
2018
Q2 		$982K Sell
35,900
-30,200
-46% -$732K 0.01% 1745
2018
Q1 		$1.39M Buy
66,100
+36,700
+125% +$903K 0.01% 1258
2017
Q4 		$565K Buy
29,400
+3,100
+12% +$71.6K ﹤0.01% 2154
2017
Q3 		$654K Buy
26,300
+9,700
+58% +$183K 0.01% 1864
2017
Q2 		$266K Sell
16,600
-400
-2% -$5.59K ﹤0.01% 2437
2017
Q1 		$240K Buy
+17,000
New +$228K ﹤0.01% 2396

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading's NTLA Position: Q1 2026 in Review

Group One Trading reduced its Intellia Therapeutics (NTLA) stake by 0.7% in Q1 2026, selling an estimated $8.1K and leaving 90,049 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Group One Trading first reported a position in NTLA in Q1 2017 and has held it in 29 quarters since. The position peaked at $4.57M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Group One Trading held 90,049 shares of Intellia Therapeutics worth $1.15M as of Q1 2026.
  • Group One Trading sold 636 Intellia Therapeutics shares in Q1 2026, an estimated $8.1K.
  • Intellia Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2577 holding.
  • Group One Trading first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 29 quarters since.
  • Group One Trading's Intellia Therapeutics position peaked at $4.57M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.